Cargando…

P1114: ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB OR ZANUBRUTINIB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): RESULTS FROM A MULTI-ARM PHASE 1B STUDY

Detalles Bibliográficos
Autores principales:	Soumerai, J. D., Jagadeesh, D., Salman, H., Samaniego, F., Patel, K., Stathis, A., Reddy, N., Kenkre, V. P., Asch, A., Diefenbach, C., Lossos, I. S., Persky, D., Awan, F., Huang, W., Vandever, K., Zelenetz, A. D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430341/ http://dx.doi.org/10.1097/01.HS9.0000847324.06186.df

Ejemplares similares

P1242: ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY ZANUBRUTINIB MAINTENANCE FOR TREAT-NAIVE PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PHASE II STUDY
por: Zhang, Y., et al.
Publicado: (2022)

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
por: Geng, Hongzhi, et al.
Publicado: (2023)

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY
por: Opat, S., et al.
Publicado: (2022)

Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

A Trp53(fl/fl)Pten(fl/fl) mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging
por: Buchakjian, Marisa R., et al.
Publicado: (2017)

Venetoclax for the treatment of translocation (11;14) AL amyloidosis
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib
por: Lynes, John, et al.
Publicado: (2022)

Complete genome sequence of Syntrophobotulus glycolicus type strain (FlGlyR(T))
por: Han, Cliff, et al.
Publicado: (2011)

Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study
por: Goto, Hideki, et al.
Publicado: (2022)

Simultaneous development of zanubrutinib in the USA and China
por: Li, Guanqiao, et al.
Publicado: (2020)

Correction: Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

P1120: THE EFFICACY AND SAFETY OF ZANUBRUTINIB AND DEXAMETHASONE IN SYMPTOMATIC WALDENSTROM MACROGLOBULINNEMIA
por: Liu, A., et al.
Publicado: (2022)

Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series
por: Zhang, Yan, et al.
Publicado: (2021)

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation
por: Diamantidis, Michael D., et al.
Publicado: (2022)

1114 Fetal demise during the COVID-19 pandemic: are rates increasing?
por: Ozimek, John A., et al.
Publicado: (2021)

Efficacy of Zanubrutinib in the Treatment of Bing–Neel Syndrome
por: Wong, Jonathan, et al.
Publicado: (2018)

Zanubrutinib for mantle cell lymphoma, Waldenström’s macroglobulinaemia
Publicado: (2021)

Zanubrutinib in lymphoproliferative disorders: a comprehensive review
por: Muñoz, Javier, et al.
Publicado: (2022)

P1093: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)
por: Thieblemont, Catherine, et al.
Publicado: (2023)

Multiple myeloma with t(11;14): impact of novel agents on outcome
por: Puertas, Borja, et al.
Publicado: (2023)

SIRPα(+) macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab
por: Marques-Piubelli, Mario L., et al.
Publicado: (2022)

P1114: HIGHLY SELECTIVE ALLOSTERIC MODULATOR OF THE PHOSPHOINOSITIDE 3-KINASE DELTA (PI3KΔ) ROGINOLISIB (IOA-244) IN A DOSE ESCALATION STUDY OF PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA (FL)
por: Carlo-Stella, Carmelo, et al.
Publicado: (2023)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First
por: Deshpande, Anagha, et al.
Publicado: (2022)

Disseminated fungal infection in a patient receiving zanubrutinib
por: Walsh, Madalyn, et al.
Publicado: (2023)

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia
por: Tam, Constantine S., et al.
Publicado: (2023)

Mast cell‐deficient mice Mcpt5Cre/Dicer ( fl/fl ) redefine the role of mast cells in experimental bullous pemphigoid
por: Nsiah‐Dosu, S., et al.
Publicado: (2021)

1114. Identifying and Addressing Knowledge Gaps in Influenza Management with Targeted Continuing Medical Education
por: Robinson, Katie, et al.
Publicado: (2020)

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
por: Tam, Constantine S., et al.
Publicado: (2022)

FL studio cookbook
por: Friedman, Shaun
Publicado: (2014)

P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE
por: Kumode, Takahiro, et al.
Publicado: (2023)

A novel UHPLC‒MS/MS method for quantitative analysis of zanubrutinib in rat plasma: application to an in vivo interaction study between zanubrutinib and triazole antifungal
por: Tang, Peng-fei, et al.
Publicado: (2023)

P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)
por: Eichhorst, Barbara, et al.
Publicado: (2023)

P1185: ANTITUMOR ACTIVITY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R-CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DLBCL WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II STUDY.
por: Li, C., et al.
Publicado: (2022)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
por: Wolska-Washer, Anna, et al.
Publicado: (2023)

Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review
por: Alsuhebany, Nada, et al.
Publicado: (2023)

Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma
por: Schaffel, R., et al.
Publicado: (2010)

PB2149: ZANUBRUTINIB IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB VERSUS R-MINICHOP IN UNFIT OR FRAIL PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA AGED OVER OR EQUAL TO 70 YEARS
por: Xu, P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5kupcq0t7c92chc7pbicharbro